Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"MitoImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MitoImmune Gets FDA Clearance of IND Application for MIT-001 for CCRT Patients with Head and Neck Cancer","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"MitoImmune Therapeutics"}]

MitoImmune Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

MitoImmune Gets FDA Clearance of IND Application for MIT-001 for CCRT Patients with Head and Neck Cancer

Details:

MIT-001 is an anti-inflammatory and anti-necrotic agent, specifically scavenging ROS in the mitochondria. MitoImmune plans to initiates a Phase 2 trial of oral mucositis (OM) prevention and is expanding OM treatment into hematopoietic stem cell transplantation.

Lead Product(s): MIT-001

Therapeutic Area: Gastroenterology Product Name: MIT-001

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY